Blog
RSS FeedPosted by Michael Wonder on 21 Aug 2018
Proposal to change the funded brand of epoetin alfa
21 August 2018 - PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin ...
Posted by Michael Wonder on 20 Aug 2018
Treatment funded in Australia, but New Zealand brother misses out
21 August 2018 - James McGoram says the genetic disease he has is yet to affect his day-to-day life but ...
Posted by Michael Wonder on 20 Aug 2018
PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible
20 August 2018 - Vertex Pharmaceuticals announces that it has received the PBAC recommendation for Orkambi (lumacaftor/ivacaftor) to be listed on ...
Posted by Michael Wonder on 20 Aug 2018
Proposal to list nintedanib (Ofev) and remove restrictions from tiotropium bromide (Spiriva)
20 August 2018 - PHARMAC is seeking feedback on a proposal to list nintedanib (Ofev) and remove the current funding ...
Posted by Michael Wonder on 20 Aug 2018
Network meta-analysis in health care decision-making
20 August 2018 - Systematic reviews and meta-analyses play a crucial role in clinical decision making. ...
Posted by Michael Wonder on 19 Aug 2018
Insights from the July 2018 PBAC meeting
20 August 2018 - Highest recommendation rate for a scheduled PBAC meeting in modern times. ...
Posted by Michael Wonder on 18 Aug 2018
Life saving cancer drug Keytruda worth $150,000 goes on the PBS
19 August 2018 - Melbourne academic and lung cancer patient John Burke has spent $80,000 on the drug that saved ...
Posted by Michael Wonder on 18 Aug 2018
Pharmaceutical Benefits Advisory Committee recommends Orkambi for PBS
17 August 2018 - Cystic fibrosis sufferers across Australia will now have access to a life-changing drug after the Federal ...
Posted by Michael Wonder on 17 Aug 2018
Hundreds of cancer patients received partial doses of medication
16 August 2018 - Hundreds of cancer patients in Canada did not receive the full dose of three highly concentrated ...
Posted by Michael Wonder on 17 Aug 2018
Recommendations made by the PBAC - July 2018
17 August 2018 - The recommendations from the July 2018 PBAC meeting are now available. ...
Posted by Michael Wonder on 17 Aug 2018
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
17 August 2018 - NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used ...
Posted by Michael Wonder on 17 Aug 2018
Post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis
17 August 2018 - The PBAC minutes pertaining to the draft review report for the post-market review of the use of ...
Posted by Michael Wonder on 16 Aug 2018
Anxious wait for cystic fibrosis PBS announcement
17 August 2018 - The outcomes from the July 2018 PBAC meeting with be made public later today. ...
Posted by Michael Wonder on 16 Aug 2018
NICE publishes draft guidance on new cellular therapy for Crohn's disease
16 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using darvadstrocel in ...
Posted by Michael Wonder on 16 Aug 2018
High and random medical gap costs revealed
16 August 2018 - The random scale and nature of out of pocket fees charged by medical specialists revealed in ...